Hua Cong, Ph.D., Professor, Department of Parasitology, Shandong University, Master's supervisor, Youth member of Society of Tropical Diseases and Parasitology.
Research interests
lStudy on the prevention and treatment of human parsites.
lVaccines and drugs againstToxoplasma gondii.
lMechanism of parasite invade human and host response, pathogenic mechanism of parasites and the relationship between parasites and host.
lImmune response caused by the parasites.
Simple introduction
Study onToxoplasma gondiivaccine and pathogenesis research since 1996. To undertake and complete the projects supported by the national and Shandong Provincial science foundations and the Provincial Science and Technology Commission research and demonstration for improving infant birth quality in Shandong Province: experimental study ofT. gondiicomplex multivalentum subunit vaccine; experimental study ofT. gondiisubunit vaccine and adjuvant effect. Between 2008 and 2016, two national natural science foundations were hosted and completed: the molecular mechanism of tlr receptor-induced signal transduction in the host activated by profilin protein ofT. gondii, and the in-depth study onT. gondiivaccine, which accumulated rich experience. In 2009 and 2017, as visiting scholars engaged in scientific research at the center for toxoplasmosis research at the university of Chicago in the united states, and made a breakthrough in the research of toxoplasmosis supermodel vaccine. So far, more than 30 sci papers have been published, four national invention patent authorizations, and the first prize for scientific research achievements in shandong province.
Work Experience
2015.09- Professor,Department of parasitology, Institute of Pathogenic Biology, Shandong University, Jinan, Shandong,China
2017.04-2018.06 Visiting Scholar,Department of Surgery, The university of
2009.04-2010.05 Chicago, Chicago, Illinois, USA
2005.09-2015,09 Associate professor,Department of parasitology, Institute of Pathogenic Biology, Shandong University, Jinan, Shandong,China
2000.09-2006.09 Lecturer,Department of parasitology, Institute of Pathogenic Biology
Shandong University, Jinan, Shandong,China
Education
01/2012~2015/12 Postdoc, Public health, Shandong univeristy,Jinan, Shandong, China
2009.04-2010.05 Postdoc,Toxoplasmosis The university of Chicago, Chicago, Illinois, USA
08/2003~ 07/2006 Ph.D. in Pathogenic Biology, Shandong University, Jinan, Shandong,
08/1996~ 07/1999 S.M.in Parasitology Shandong Medical University, Jinan China
09/1989~ 07/1992 B.S.A. in Public Health Shandong Medical University, Jinan , China
Teaching subjects
Courses Students
Medical parasitology for chinese and international clinic medicine students
Experiment of Parasitology for chinese and international clinic medicinestudents
Infection and Immunity foreight-year medical students
PBL class for chinese and international clinic medicine students
English paper writing forchinese and international clinic medicine students
Research Experience
1.Molecular Mechanism and intervention Strategy of Host Mental and Behavioral
abnormalities caused by Toxoplasma gondii infection (zr2017mh043).
2.Study on Toxoplasma chitosan Nano-sustained release Vaccine based on dominant
peptides.Key R & D Project of Shandong Province (Grant No.: 2016gsf201201).
3.HLA-restricted epitopes vaccine againstToxoplasma gondiifunded by theNational
Natural Science Foundation of China. (NSFC81171604)
4. Supermotif vaccine againstToxoplasma gondiifor human use. (NIH and NSFC)
5.Leader investigator for research project ofStudy on the molecular mechanism of TLR11 signaling pathway activation by Profilin ofToxoplasma gondiifunded by theNational Natural Science Foundation of China
6. Leader investigator for research project ofStudy on the mucosal immunity of multi-stage and multi-epitope DNA vaccine againstToxoplasma gondiifunded bythe Basic Medical Research Program of Shandong Province
7. Leader investigator for research project ofStudy on the oral immunization with a live recombinant attenuatedSalmonella typhimuriumprotect mice againstToxoplasma gondiifunded by the Basic Medical Research Program of Shandong Province.
8. A major participant ofthe study on the multi-component subunit vaccine ofToxoplasma gondii.(Grant fromthe Natural Science Foundation of Shandong Province
Publications
1. Guo J, Zhou A, Sun X, Sha W, Ai K, Pan G, Zhou C, Zhou H,Cong H*, He S*.
Immunogenicity of a Virus-Like-Particle Vaccine Containing Multiple Antigenic Epitopes of Toxoplasma gondii Against Acute and Chronic Toxoplasmosis in Mice.
Front Immunol. 2019 Mar 29;10:592.
2.Wang T＃, Sun X＃, Qin W, Zhang X, Wu L, Li Y, Zhou C, Zhou H, He S,Cong H*.
From inflammatory reactions to neurotransmitter changes: Implications for understanding the neurobehavioral changes in mice chronically infected with Toxoplasma gondii.Behav Brain Res. 2019；359：737-748.
3. Guo J＃, Sun X＃, Yin H, Wang T, Li Y, Zhou C, Zhou H, He S*,Cong H*.Chitosan microsphere used as an effective system to deliver a linked antigenic peptides vaccine protect mice against acute and chronic Toxoplasmosis.Front Cell Infect Microbiol. 2018 May 23;8:163.
4. Wang T＃, Yin H＃, Li Y＃, Zhao L, Sun X,Cong H*.Vaccination with recombinant adenovirus expressing multi-stage antigens of Toxoplasma gondii by the mucosal route induces higher systemic cellular and local mucosal immune responses than with other vaccination routes.Parasite. 2017;24:12.
5. Yin H＃, Zhao L＃, Wang T, Zhou H, He S,Cong H*.A Toxoplasma gondii vaccine encoding multistage antigens in conjunction with ubiquitin confers protective immunity to BALB/c mice against parasite infection.Parasit Vectors. 2015;8(1):498.
6. Zhao L,Zhang M,Cong H＊．Advances in the study of HLA-restricted epitope vaccines. Human Vaccines & Immunotherapeutics. 2014;1:2566-77.
7. Cong H＊,Yuan Q,Zhao Q,Zhao L,Yin H,Zhou H,He S,Wang Z*. Comparative efficacy of a multi-epitope DNA vaccine via intranasal, peroral, and intramuscular delivery against lethal Toxoplasma gondii infection in mice. Parasit Vectors. 2014; 7: 145.
8. Zhang M,Zhao L,Song J,Li Y,Zhao Q,He S,Cong H*. DNA vaccine encoding the Toxoplasma gondii bradyzoite-specific surface antigens SAG2CDX protect BALB/c mice against type II parasite infection. Vaccine. 2013; 31(41): 4536-40.
9. Cong H＊, Zhang M, Xin Q, Wang Z, Li Y, Zhao Q, Zhou H, He S. Compound DNA vaccine encoding SAG1/SAG3 with A2/B subunit of cholera toxin as a genetic adjuvant protects BALB/c mice against Toxoplasma gondii. Parasit Vectors. 2013; 13;6:63.
10. Cong H＊, Zhang M, Zhang Q, Gong J, Cong H, Xin Q, He S. Analysis of structures and epitopes of surface antigen glycoproteins expressed in bradyzoites of Toxoplasma gondii. Biomed Res Int. 2013;2013:165342.
11. Cong H, Mui EJ, Witola WH, Sidney J, Alexander J, Sette A, Maewal A, Bissati KE, Zhou Y, Suzuki Y, Lee D, Stuart Woods, Caroline Sommerville, Fiona L. Henriquez, Craig W. Roberts, Rima McLeod*.Toxoplasma gondii HLA-B*0702-restricted GRA720-28 peptide with adjuvants and a universal helper T cell epitope elicits CD8+ T cells producing interferon-γ and reduces parasite burden in HLA-B* 0702 mice. Human Immunology. 2012;73(1):1-10.
12. Cong H, Mui EJ, Witola WH, Sidney J, Alexander J, Sette A, Maewal A, McLeod R*. Towards an immunosense vaccine to prevent toxoplasmosis: protectiveToxoplasma gondiiepitopes restricted by HLA-A*0201.Vaccine. 2011;29(4):754-62.
13. Cong H, Mui EJ, Witola WH, Sidney J, Alexander J, Sette A, Maewal A, McLeod R＊. Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+T cell epitope based, adjuvanted vaccine protective againstToxoplasma gondii.Immunome Res. 2010;6:12.
14. Cong H,Gu QM*,Yin HE,Wang JW,ZhaoQL,Zhou HY,Li Y,Zhang JQ. Multi-epitope DNA vaccine linked to the A2/B subunit of cholera toxin protect mice against Toxoplasma gondii.Vaccine. 2008;26(31):3913-21.
15. Cong H, Gu QM, Jiang Y, He SY, Zhou HY, Yang TT, Li Y, Zhao QL.Oral immunization with a live recombinant attenuated Salmonella typhimurium protects mice againstToxoplasma gondii.Parasite Immunol. 2005;27(1-2):29-35.
16.Tan TG,Mui E,Cong H,Witola WH,Montpetit A,Muench SP,Sidney J,Alexander J,
Sette A,Grigg ME,Maewal A,McLeod R. Identification ofT. gondiiepitopes,
adjuvants, and host genetic factors that influence protection of mice and humans.
Vaccine.2010 May 21;28(23):3977-89.
17. Henriquez FL, Woods S,Cong H, McLeod R, Roberts CW.Immunogenetics of
Toxoplama gondiiinforms vaccine design.Trends Parasitol.2010 Nov;26(11):550-5.
Authorized patent:
1.CN201510563790.The complex epitope peptide of the toxoplasmosis and the prepared vaccine 2018.07.03, China
2.CN201410345709. A multivalent adenovirus vaccine for the prevention of toxoplasmosis. 2017.1.11 China .
3.CN201310204704. The dominant epitopes of the cd8 t cells of the toxoplasma gondii antigen 2016.4 China .
4.CN201310201888.0 DNA vaccine are used to prevent the chronic toxoplasmosis in humans or animals. 2013.5.27 china
Awards and Honors
2015 The first prize for research work on theT. gondiivaccine of Shandong university
2012-2014 Excellent teaching prize, Shandong university,China
2007 Excellent Doc-graduate Scholarship, Shandong University, China
2006Excellent Teacher Prize, Shandong University, China
2005Excellent Graduate Academic Scholarship, Shandong University, China
2004The first prize for teaching in English, Shandong University, China
2003 Research fellowship, School of Medicine, Shandong University, China
2000 1stprize award, The Symposium of 5thCongress of Shandong Society of Microbiology, China
1999 Excellent Graduated student, Shandong Medical University, China
Contact information
Monday~Friday 8:00-5:00
Office: No.5 building 5311
Tel 86-531-88382042
13153107210 (cell phone)
E-mail conghua@sdu.edu.cn
